116 related articles for article (PubMed ID: 35688358)
1. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial.
Kurokawa Y; Honma Y; Sawaki A; Naito Y; Iwagami S; Komatsu Y; Takahashi T; Nishida T; Doi T
Ann Oncol; 2022 Sep; 33(9):959-967. PubMed ID: 35688358
[TBL] [Abstract][Full Text] [Related]
2. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
Adenis A; Blay JY; Bui-Nguyen B; Bouché O; Bertucci F; Isambert N; Bompas E; Chaigneau L; Domont J; Ray-Coquard I; Blésius A; Van Tine BA; Bulusu VR; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Le Cesne A
Ann Oncol; 2014 Sep; 25(9):1762-1769. PubMed ID: 25122671
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of post-first-line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta-analysis.
Hu K; Zhang H; Shu M; Wang X
Cancer Med; 2023 Jun; 12(11):12187-12197. PubMed ID: 37084005
[TBL] [Abstract][Full Text] [Related]
4. Pimitespib for the treatment of advanced gastrointestinal stromal tumors and other tumors.
Doi T; Yamamoto N; Ohkubo S
Future Oncol; 2024 Mar; 20(9):507-519. PubMed ID: 38050698
[TBL] [Abstract][Full Text] [Related]
5. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
Bauer S; Jones RL; Blay JY; Gelderblom H; George S; Schöffski P; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Su Y; Meade J; Wang T; Sherman ML; Ruiz-Soto R; Heinrich MC
J Clin Oncol; 2022 Dec; 40(34):3918-3928. PubMed ID: 35947817
[TBL] [Abstract][Full Text] [Related]
6. Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours.
Naito Y; Nishida T; Doi T
Gastric Cancer; 2023 May; 26(3):339-351. PubMed ID: 36913072
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.
Faivre S; Niccoli P; Castellano D; Valle JW; Hammel P; Raoul JL; Vinik A; Van Cutsem E; Bang YJ; Lee SH; Borbath I; Lombard-Bohas C; Metrakos P; Smith D; Chen JS; Ruszniewski P; Seitz JF; Patyna S; Lu DR; Ishak KJ; Raymond E
Ann Oncol; 2017 Feb; 28(2):339-343. PubMed ID: 27836885
[TBL] [Abstract][Full Text] [Related]
8. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.
Symcox M; Jones RL
Future Oncol; 2023 Nov; 19(36):2383-2393. PubMed ID: 37594164
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China.
Li J; Zhang J; Zhang Y; Qiu H; Zhou Y; Zhou Y; Zhang X; Zhou Y; Zhu Y; Li Y; Wang M; Shen K; Tao K; Wu X; Wang H; Zhang B; Ling J; Ye Y; Wu X; Qu H; Ma Y; Jiao X; Zheng H; Jin J; Liu Z; Tan M; Fang Y; Zhang P; Zhang N; Lei C; Cai Z; Liang B; Peng Z; Huang Z; Dong J; Shen L
Eur J Cancer; 2024 Jan; 196():113439. PubMed ID: 37980854
[TBL] [Abstract][Full Text] [Related]
10. Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data.
Mohammadi M; IJzerman NS; Hollander DD; Bleckman RF; Oosten AW; Desar IME; Reyners AKL; Steeghs N; Gelderblom H
Target Oncol; 2023 May; 18(3):415-423. PubMed ID: 37079223
[TBL] [Abstract][Full Text] [Related]
11. Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor.
Chi P; Qin LX; Nguyen B; Kelly CM; D'Angelo SP; Dickson MA; Gounder MM; Keohan ML; Movva S; Nacev BA; Rosenbaum E; Thornton KA; Crago AM; Yoon S; Ulaner G; Yeh R; Martindale M; Phelan HT; Biniakewitz MD; Warda S; Lee CJ; Berger MF; Schultz ND; Singer S; Hwang S; Chen Y; Antonescu CR; Tap WD
J Clin Oncol; 2022 Mar; 40(9):997-1008. PubMed ID: 35041493
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study.
Riedel RF; Ballman KV; Lu Y; Attia S; Loggers ET; Ganjoo KN; Livingston MB; Chow W; Wright J; Ward JH; Rushing D; Okuno SH; Reed DR; Liebner DA; Keedy VL; Mascarenhas L; Davis LE; Ryan C; Reinke DK; Maki RG
Oncologist; 2020 Nov; 25(11):e1655-e1662. PubMed ID: 32701199
[TBL] [Abstract][Full Text] [Related]
13. Long-term response to pimitespib in postoperative recurrent gastrointestinal stromal tumors with PDGFRA D842V mutation: a case report.
Teranishi R; Takahashi T; Kurokawa Y; Saito T; Yamamoto K; Yamashita K; Tanaka K; Makino T; Nakajima K; Eguchi H; Doki Y
Surg Case Rep; 2023 Apr; 9(1):54. PubMed ID: 37027098
[TBL] [Abstract][Full Text] [Related]
14. Pimitespib: First Approval.
Hoy SM
Drugs; 2022 Sep; 82(13):1413-1418. PubMed ID: 35986838
[TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor.
Kumar V; Doros L; Thompson M; Mushti SL; Charlab R; Spehalski EI; Zhao H; Thompson MD; Tang S; Pazdur R; Lemery SJ; Theoret MR; Fashoyin-Aje LA
Clin Cancer Res; 2023 Jun; 29(11):2020-2024. PubMed ID: 36485007
[TBL] [Abstract][Full Text] [Related]
16. Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience.
Lin LC; Huang WK; Yen CC; Yang CY; Sung MT; Wong NS; Chua DTT; Lee SWM; Chen JS; Yeh CN
Front Oncol; 2022; 12():883399. PubMed ID: 35847924
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and network meta-analysis of the efficacy and safety of third-line and over third-line therapy after imatinib and TKI resistance in advanced gastrointestinal stromal tumor.
Xiao X; Yuan W; Wang C; Song H
Front Pharmacol; 2022; 13():978885. PubMed ID: 36479203
[TBL] [Abstract][Full Text] [Related]
18. A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours.
Kim HD; Yoo C; Ryu MH; Kang YK
Br J Cancer; 2023 Aug; 129(2):275-282. PubMed ID: 37179439
[TBL] [Abstract][Full Text] [Related]
19. Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors.
Thirasastr P; Somaiah N
Clin Exp Gastroenterol; 2023; 16():11-19. PubMed ID: 36798653
[TBL] [Abstract][Full Text] [Related]
20. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
Gounder MM; Razak AA; Somaiah N; Chawla S; Martin-Broto J; Grignani G; Schuetze SM; Vincenzi B; Wagner AJ; Chmielowski B; Jones RL; Riedel RF; Stacchiotti S; Loggers ET; Ganjoo KN; Le Cesne A; Italiano A; Garcia Del Muro X; Burgess M; Piperno-Neumann S; Ryan C; Mulcahy MF; Forscher C; Penel N; Okuno S; Elias A; Hartner L; Philip T; Alcindor T; Kasper B; Reichardt P; Lapeire L; Blay JY; Chevreau C; Valverde Morales CM; Schwartz GK; Chen JL; Deshpande H; Davis EJ; Nicholas G; Gröschel S; Hatcher H; Duffaud F; Herráez AC; Beveridge RD; Badalamenti G; Eriksson M; Meyer C; von Mehren M; Van Tine BA; Götze K; Mazzeo F; Yakobson A; Zick A; Lee A; Gonzalez AE; Napolitano A; Dickson MA; Michel D; Meng C; Li L; Liu J; Ben-Shahar O; Van Domelen DR; Walker CJ; Chang H; Landesman Y; Shah JJ; Shacham S; Kauffman MG; Attia S
J Clin Oncol; 2022 Aug; 40(22):2479-2490. PubMed ID: 35394800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
